Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
House Democrats question if Valeant is wrongfully withholding records
Source: Reuters
Business | Tue Apr 26, 2016 1:09pm EDT
House Democrats question if Valeant is wrongfully withholding records
WASHINGTON | BY SARAH N. LYNCH
Democrats on a powerful U.S. congressional panel are questioning whether Canada-based Valeant Pharmaceuticals may be wrongfully withholding documents in connection with its ongoing probe into sky-rocketing drug prices, according to an internal memo seen by Reuters on Tuesday.
The memo, which was sent to Democratic members of the House of Representatives Committee on Oversight and Government Reform from the staff of its top Democrat Elijah Cummings, reveals that Valeant previously withheld readily available analyst reports prepared by banks such as Goldman Sachs, saying they were protected by attorney-client privilege.
The memo says it also raises questions about other documents that are still being withheld, saying some of these "were not drafted by attorneys and do not include communications with attorneys."
A spokesperson for Valeant did not immediately respond to a request for comment.
The April 26 memo comes just one day before three of Valeant's top executives are slated to appear before a different U.S. Senate panel that is also investigating high drug prices.
[font size=1]-snip-[/font]
House Democrats question if Valeant is wrongfully withholding records
WASHINGTON | BY SARAH N. LYNCH
Democrats on a powerful U.S. congressional panel are questioning whether Canada-based Valeant Pharmaceuticals may be wrongfully withholding documents in connection with its ongoing probe into sky-rocketing drug prices, according to an internal memo seen by Reuters on Tuesday.
The memo, which was sent to Democratic members of the House of Representatives Committee on Oversight and Government Reform from the staff of its top Democrat Elijah Cummings, reveals that Valeant previously withheld readily available analyst reports prepared by banks such as Goldman Sachs, saying they were protected by attorney-client privilege.
The memo says it also raises questions about other documents that are still being withheld, saying some of these "were not drafted by attorneys and do not include communications with attorneys."
A spokesperson for Valeant did not immediately respond to a request for comment.
The April 26 memo comes just one day before three of Valeant's top executives are slated to appear before a different U.S. Senate panel that is also investigating high drug prices.
[font size=1]-snip-[/font]
Read more: http://www.reuters.com/article/us-usa-house-valeant-idUSKCN0XN28Z?il=0